ASGCT covers cell and gene therapy specifically, not biotech broadly, which makes it one of the sharpest filters on the calendar for that modality. A company exhibiting or presenting here is telling you directly that it has an active cell or gene therapy program, which is exactly the account a CDMO or tools vendor in that space is looking for.
What ASGCT is
The American Society of Gene and Cell Therapy Annual Meeting focuses on cell and gene therapy: viral and non-viral vectors, gene editing, engineered cell therapies, and the manufacturing and analytical science that supports them. It draws a narrower, more specialized audience than a general biotech show, cell and gene therapy developers alongside the CDMOs, contract manufacturers, and analytical and tools vendors that serve advanced therapy production and testing.
The GTM signal at ASGCT
Exhibiting at ASGCT is a stronger, more specific signal than exhibiting at a broad show, because the audience filter is already done: a booth means budget committed to visibility in front of a cell and gene therapy crowd. A named presenter tied to a specific program or dataset is an equally sharp contact-level hook. Even attendance alone is a tighter filter here than at a broad meeting, since the audience itself is already modality-specific. See selling around life science conferences for how to weigh the three signals.
The outreach window
Exhibitor lists and accepted abstracts become public in the weeks before the meeting, giving a lead-time window to cross-reference the roster against your cell and gene therapy account list and plan specific, timely outreach before the show opens. On-site outreach during the meeting works as a fallback for accounts identified late. The useful follow-up window after ASGCT closes runs a few weeks before a reference to the meeting stops reading as current.
Who this matters most for
A CDMO with vector, cell processing, or advanced-therapy manufacturing capability should treat ASGCT as one of the highest-signal shows on the calendar, since the audience is a near-direct match for that buyer. A tools or services vendor serving cell and gene therapy workflows, from analytical development to release testing, will find a tighter fit here than at any general biotech or oncology show. A CRO running cell and gene therapy trials should watch ASGCT activity closely for the same reason.